Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment.
Review published in Expert review of hematology (2021)
Abstract
Introduction: Immune-mediated heparin-induced thrombocytopenia (HIT) is an infrequent complication following heparin exposure but with potentially fatal outcome due to thrombotic complications. Prompt suspension of heparin is necessary if HIT is suspected, followed by initiation of non-heparin anticoagulant therapy.Areas covered: In this review, the pathophysiology and challenges in diagnosing HIT are elucidated. Current and emerging treatment options are discussed with special focus on parenteral thrombin inhibitors (argatroban, bivalirudin), parenteral factor Xa inhibitors (danaparoid, fondaparinux) and direct oral anticoagulants (DOACs [rivaroxaban, apixaban, dabigatran]) including dosing strategies for DOACs. The database PubMed was employed without time boundaries.Expert opinion: Only argatroban holds regulatory approval for HIT treatment in both U.S. and Europe. This treatment is, however, challenged by the need for close monitoring and high costs. Fondaparinux has been increasingly used for off-label treatment and during recent years, evidence for the use of DOACs has emerged. Preliminary results from observational studies hold promise for future use of DOACs in the acute and subacute phase of HIT. However, so far, the use of DOACs in acute HIT should be reserved for clinically stable patients without severe thrombotic complications. Importantly, both fondaparinux and DOAC use is contraindicated in severe renal insufficiency.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
: Immune-mediated heparin-induced thrombocytopenia (HIT) is an infrequent complication following heparin exposure but with potentially fatal outcome due to thrombotic complications. Prompt suspension of heparin is necessary if HIT is suspected, followed by initiation of non-heparin anticoagulant...
Por qué esto importa para la hirudoterapia
Esta revisión describe la fisiopatología, el diagnóstico y el tratamiento de la trombocitopenia inducida por heparina (TIH) inmunitaria, enfatizando la necesidad de suspender inmediatamente la heparina e iniciar anticoagulantes no heparínicos. Se analizan las funciones clínicas de diversas terapias, incluidos los inhibidores directos de la trombina parenterales (argatrobán, bivalirudina), los inhibidores del factor Xa parenterales y los anticoagulantes orales directos. La relevancia para ASH radica en la discusión de los inhibidores directos de la trombina, específicamente la bivalirudina, que es un derivado sintético basado en la hirudina aislada originalmente de la saliva de la sanguijuela. La revisión subraya la demanda clínica de anticoagulantes no heparínicos, un ámbito en el que los compuestos derivados de sanguijuelas tienen importancia histórica. Sin embargo, no se discuten sanguijuelas ni hirudoterapia real; el enfoque se centra estrictamente en las estrategias modernas de manejo farmacológico.
Citación
Heparin-induced thrombocytopenia: pathophysiology, diagnosis and treatment.
Hvas et al. · Expert review of hematology, 2021
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026